Skip to ContentSkip to Navigation
Over onsFaculty of Science and EngineeringOnderzoekGRIPPharmacoTherapy, -Epidemiology & -Economics (PTEE)Publications

Publications 2004

Below our publications are listed using several headings. Scientific publications relate to original research, often published internationally, but also in the Dutch language. Professional publications are in Dutch and relate to reviews and expressions of opinions.

A few publications have no links. Reprints can be requested by our secretary

Scientific publications international
1

van Bergen JEAM, Postma MJ, Peerbooms PGH, Spangenberg AC, Tjen-A-Tak J, Bindels PJE. Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Ansterdam using mailed home-collected urine samples. International Journal of STD & AIDS 2004;15:797-802.

2

Biegert C, Wagner I, Lüdtke R, Kötter I, Lohmüller C, Günaydin I, Taxis K, Heide L. Efficacy and safety of willow bark extract in the treatmant of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. The Journal of Rheumatology 2004;31:2121-30.

3

Bos JM, Beutels PH, Annemans L, Postma MJ. Valuing prevention through economic evaluation. Pharmacoeconomics 2004;22(18):1171-9.

4

Bos JM, Postma MJ. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? Expert Reviews Pharmacoeconomics Outcomes research 2004;4(3):127-30.

5

Dautzenberg PLJ, Mulder LJ, Olde Rikkert MGM, Wouters CJ, Loonen AJM. Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage. International Journal of Geriatric Psychiatry 2004;19:641-4.

6

Dautzenberg PLJ, Mulder LJ, Olde Rikkert MGM, Wouters CJ, Loonen AJM. Adding rivastigmine to antipsychotics in the treatmant of a chronic delirium. Age and Ageing 2004;33(5):516-7.

7

Deneer VHM, Lie-A-Huen L, Kingma JH, Proost JH, Gossen SA, Stuurman A, UytdeHaag GMM, Dunselman PHJM, Brouwers JRBJ. Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. Eur J Clin Pharmacol 2004;60:693-701.

8

Deneer VHM, Borgh MBI, Kingma JH, Lie-A-Huen L, Brouwers JRBJ. Oral antiarrhytmic drugs in converting recent onset atrial fibrillation. Pharmacy World & Science 2004;26(2):66-78.

9

van Dijk KN, Plat AW, van Dijk AAC, Piersma-Wichers M, de Vries-Bots AMB, Slomp J, de Jong-van den Berg LTW, Brouwers JRBJ. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 2004;91:95-101.

10

van Driel D, Wesseling J, ter Huurne K, Geven-Boere LM, Rosendaal FR, van der Veer E, de Jong-van den Berg LTW. Adherence to a guideline for coumarins in pregnancy. Pharmacy World & Science 2004;26:297-300.

11

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Drug safety is at risk by unclear dosage instructions. Krankenhauspharmazie 2004;25(11):497.

12

Gansevoort RT, de Jong PE, Postma MJ. Cost-effectiveness of screening for Proteinuria. JAMA 2004;291(12):1442-3.

13

de Gier JJ. Trend watching for pharmacy information. International Pharmacy Journal 2004;18:13-4.

14 de Gier JJ. Categorization of effects of medicinal drugs on skilled performance: an international approach. International Pharmacy Journal 2004;18:31-3.
15

van Grootheest AC, Olsson S, Couper M, de Jong-van den Berg LTW. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiology and Drug Safety 2004;13:457-64.

16

van Grootheest AC, de Jong-van den Berg LTW. Patients' role in reporting adverse drug reactions. Drug Safety 2004;3(4):363-8.

17

van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LTW. Do pharmacists' reports of adverse drug reactions reflect patients' concerns? Pharmacy World & Science 2004;26:155-9.

18

Hoven J, Haaijer-Ruskamp F, Vander Stichele R. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM,13-15 May 2004). Eur J Clin Pharmacol 2004;60:831-4.

19

van Hulst M, Slappendel R, Postma MJ. The pharmacoeconomics of alternatives to allogeneic blood transfusion. Transfusion Alternatives in Transfusion Medicine 2004;6(1):29-36.

20

Jansen TLThA, Reinders MK, van Roon EN, Brouwers JRBJ. Benzobromarone withdrawn from the European market: another case of absence of evidence is evidence of absence. Clinical Exp Rheumatology 2004;22(5):651.

21

Jansman FGA, Postma MJ, van Hartskamp D, Willemse PHB, Brouwers JRBJ. Cost-Benefit Analysis of Capeditabine Versus 5-Fluorouracil/Leucovorin in the Treatment of Colorectal Cancer in the Netherlands. Clinical Therapeutics 2004;26(4):579-89.

22

Klok RM, van der Veen WJ, van der Werf GTh, van den Berg PB, Brouwers JRBJ, Postma MJ. Pharmacoeconomics of Gastrointestinal Drug Utilisation Prior and Post Helicobacter Pylori Eradication. Helicobacter 2004;9(1):87-91.

23

Klok RM, Postma MJ. Four quadrants of the cost-effectiveness plane: some considertations on the south-west quadrant. Expert Reviews Pharmacoeconomics Outcomes research 2004;4(6):599-601.

24

Klumpers UMH, Timmerman L, Loonen AJM, Tulen JHM, Fekkes D, Boomsma F. Responsivity to stress in chronic posttraumatic stress disorder due to childhood sexual abuse. Psychological Reports 2004;94:408-10.

25

Klumpers UMH, Boom K, Janssen FMG, Tulen JHM, Loonen AJM. Cardiovasculair risk factors in outpatients with Bipolar Disorder. Pharmacopsychiatry 2004;37:211-6.

26

Knijff-Dutmer EAJ, Postma MJ, van der Palen J, Brouwers JRBJ, van de Laar MAFJ. Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a coohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. Clinical Therapeutics 2004;26(7):1160-7.

27

Meijer WM, de Smit DJ, Jurgens RA, de Jong-van den Berg LTW. Pharmacists' role in improving awareness about folic acid: a pilot study on the process of introducing an intervention in pharmacy practice. International Journal of Pharmacy Practice 2004;12:29-35.

28

Mookhoek EJ, Loonen AJM. Retrospective evaluation of the effect of omeprazole on clozapine metabolism. Pharmacy World & Science 2004;26:180-2.

29

Movig KLL, Mathijssen MPM, Nagel PHA, van Egmond T, de Gier JJ, Leufkens HGM, Egberts ACG. Psychoactive substance use and the risk of motor vehicle accidents. Accident Analysis & Prevention 2004;36:631-6.

30

Postma MJ, Sagoe KWC, Dronkers F, Sprenger HG, de Jong-van den Berg LTW, Beck EJ. Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects. Expert Opin Pharmacotherapy 2004;5(3):521-8.

31

Postma MJ, Bos JM, Beutels PH, Schilthuis H, van den Hoek JAR. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 2004;22:1862-7.

32

Postma MJ, Bos JM, Welte R, de Groot R, Luytjes W, Rümke HC, Beutels PH. Do costs of varicella justify routine infant vaccination? European Journal of Health Economics 2004;1:54-7.

33

Räth K, Taxis K, Walz G, Gleiter CH, Li S-M, Heide L. Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of artemisia annua L. (annual wormwood). The American Society of Tropical Medicine and Hygiene 2004;70(2):128-32.

34

Rijcken CAW, Tobi H, Vergouwen ACM, de Jong-van den Berg LTW. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data. Pharmacoepidemiology and Drug Safety 2004;13:365-70.

35 van Roon EN, Jansen TLThA, Mourad L, Houtman PM, Bruyn GAW, Griep EN, Wilffert B, Tobi H, Brouwers JRBJ. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. British Journal of Clinical Pharmacology 2004;58(2):201-8.
36

van Roon EN, Jansen TLThA, van de Laar MAFJ, Janssen M, Yska JP, Keuper R, Houtman PM, Brouwers JRBJ. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide. Serum concentrations predict response to therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2004;sept 2(PMID: 15345501).

37

van Roon EN, Yska JP, Raemaekers J, Jansen TLThA, van Wanrooy M, Brouwers JRBJ. A rapid and simple determination of A77 1726 in humand serum by high-performance liquid chromatography and its application for optimization therapy. Journal of Pharmaceutical and Biomedical Analysis 2004;36:17-22.

38

van Roon EN, Jansen TLThA, Houtman NM, Spoelstra P, Brouwers JRBJ. Leflunomide for the treatment of rheumatoid arthritis in clinical practice. Incidence and Severity of Hepatotoxicity. Drug Safety 2004;27(5):345-52.

39

Schirm E, Tobi H, de Jong-van den Berg LTW. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. Journal of Clinical Epidemiology 2004;57:737-41.

40

Schirm E, Schwagermann MP, Tobi H, de Jong-van den Berg LTW. Drug use during breastfeeding. A survey from the Netherlands. European Journal of Clinical Nutrition 2004;58(2):386-90.

41

Schirm E, Meijer WM, Tobi H, de Jong-van den Berg LTW. Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system. European Journal of Obestetrics & Gynecology 2004;114:182-8.

42

Schirm E, Tobi H, van Puijenbroek EP, Monster-Simons MH, de Jong-van den Berg LTW. Reported adverse drug reactions and their determinants in Dutch children outside the hospital. Pharmcoepidemiology and Drug Safety 2004;13:159-65.

43

Schirm E, Monster TBM, de Vries R, van den Berg PB, de Jong-van den Berg LTW, Tobi H. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiology and Drug Safety 2004;13:173-9.

44

Schirm E, Pedersen L, Tobi H, Nielsen GL, Sørensen HT, de Jong-van den Berg LTW. Drug use among fathers around time of conception: two register based surveys from Denmark and The Netherlands. Pharmacoepidemiology and Drug Safety 2004;13:609-13.

45

Smink BE, Brandsma JE, Dijkhuizen A, Lusthof KJ, de Gier JJ, Egberts ACG, Uges DRA. Quantitative analysis of 33 benzodiazepines, metabolites and benzodiazepine-like substances in whole blood liquid chromatography-(tandem) mass spectrometry. Journal of Chromatography B 2004;811:13-20.

46

Sramkova P, de Jong-van den Berg LTW, Oerlemans APWM. Comparison of Dutch and Czech systems of pharmacy studies. Pharmacy Education 2004;4(3/4):153-63.

47

Stuurman-Bieze A, van den Berg PB, Tromp ThFJ, de Jong-van den Berg LTW. Computer-assisted medication review for asthmatic patients as a base for intervention. Pharmacy World & Science 2004;26(5):289-96.

48

Taxis K, Wirtz V, Barber N. Variations in aseptic techniques during preparation and administration of intravenous drugs-an observation-based study in the UK and in Germany. Journal of Hospital Infection 2004;56(1):79-81.

49

Taxis K, Barber N. Incidence ans severity of intravenous drug errors in a German hospital. Eur J Clin Pharmacol 2004;59(11):815-7.

50

Taxis K, Barber N. Causes of intravenous medication errors-observation of nurses in a German hospital. Journal Public Health 2004;12:132-8.

51

Taxis K. Medikationsfehler in Deutschen Krankenhäusern. Krankenhauspharmazie 2004;25(11):465-70.

52

Tobi H, van den Heuvel N-JN, de Jong-van den Berg LTW. Does uncollected medication reduce the validity of pharmacy dispensing data? Pharmacoepidemiology and Drug Safety 2004;13:497-500.

53

Tramarin A, Postma MJ, Gerzeli S, Campostrini S, Starace F. The clinical and economic efficacy of HAART: a shift from inpatient medical to outpatient pharmaceutical care for HIV/AIDS patients in Northeastern Italy. AIDS Care 2004.

54

Tramarin A, Parise N, Campostrini S, Yin DD, Postma MJ, Lyu R, Grisetti R, Capetti A, Cattelan AM, Di Toro MT, Mastroianni A, Pignattari E, Mondardini V, Calleri G, Raise E, Starace F. Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretreviral therapy. Quality of Life Research 2004;13:243-50.

55

Tramarin A, Campostrini S, Postma MJ, Calleri G, Tolley K, Parise N, de Lalla F. A Multicentre Study of Patient Survival, Disability, Quality of life and Cost of Care. Pharmacoeconomics 2004;22(1):43-53.

56

de Vries TW, de Jong-van den Berg LTW, Hadders-Algra M. Paroxetine during lactation: is it realy safe for the infant? Acta Paediatrica 2004;93:1406-7.

57

van der Werf JJ, Dekens-Konter JAM, Brouwers JRBJ. A new model for teaching Pharmaceutical Care Services Management. Pharmacy Education 2004;4(3/4):165-9.

58

Walsh JM, de Gier JJ, Christopherson AS, Verstraete AG. Drugs and Driving. Traffic Injury Prevention 2004;5(3):241-53.

60

Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, Rümke HC, Postma MJ. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making. Vaccine 2004;23:470-9.

61

Zijlstra GS, Boersma C, Frijlink HW, Postma MJ. Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis. Expert Reviews Pharmacoeconomics Outcomes research 2004;4(1):49-59.

Scientific publications national
1

Ajubi NE, al Hadithy AFY, Brouwers JRBJ, Storm H, Wilffert B. Determination of dopamine receptor (D2)-141C Ins/Del polymorphism in wholeblood and buccal swabs by PCR-RFLP genotype using GC-Rich® solution. Ned Tijdschr Klin Chem Labgeneesk 2004;29(5):263-5.

2

Boersma C, van den Berg PB, Klok RM, de Jong-van den Berg LTW, Postma MJ. Gebruikseffecten rond het aflopen van de patenten op omeprazol en simvastatine. Wel generieke substitutie, geen resubstitutie. Pharmaceutisch Weekblad 2004;139(49):1639-42.

3

Botta-Steeneken NA, van Roon EN, Jansen TLTA, Keuper R, Wu MD, Brouwers JRBJ. Optimalisering van leflunomidetherapie. TDM bevestigt verband tussen spiegel en respons. Pharmaceutisch Weekblad 2004;139(29/30):978-81.

4

Brouwers JMM, Briët JW, Brouwers JRBJ. Weeënstorm na cervixrijping met dinoproston in een vaginaal afgiftesysteem. Nederlands Tijdschrift Geneeskunde 2004;148(26):1300-3.

5

Fijn R, Lenderink AW, Egberts ACG, Brouwers JRBJ, de Jong-van den Berg LTW. Farmaco-epidemiologisch model levert indicatoren voor non-conform voorschrijfgedrag. Naleving ziekenhuisformularia strandt niet op personen. Pharmaceutisch Weekblad 2004;139(47):1550-3.

6

al Hadithy AFY, de Boer NKH, Derijks LJJ, Mulder CJJ, Brouwers JRBJ. Farmacogenetica en bloedspiegelbepalingen bij thiopurines. Individualisering van therapie bij inflammatoire darmziekten. Pharmaceutisch Weekblad 2004;139(52/53):1744-7.

7

Hugtenburg JG, Faber A, Schirm E, de Boer I, Tobi H, Heerdink ER, Tso YH. Methylfenidaat bij kinderen: gebruik en ervaringen in Nederland. Tijdschrift voor Psychiatrie 2004;46(1):31-7.

8

Jansman FGA, Jansen JA, Coenen JLLM, de Graaf J, Smit WM, Brouwers JRBJ. Klinisch relevante interacties van fluorouracil + leucovorine bij patiënten met colorectale kanker. Meer voer voor de interactiebestanden. Pharmaceutisch Weekblad 2004;139(42):1392-6.

9

de Jong JCF, van den Berg PB, Tobi H, de Jong-van den Berg LTW. Combinatie van SSRI's met NSAID's vergroot kans op maagbezwaren. Interactie vertienvoudigt bijwerking. Pharmaceutisch Weekblad 2004;139(13):451-5.

10

Lems WF, Samsom M, Brouwers JRBJ, Hamdy NAT, Mulder CJ, Schobben AFAM, Juttman JR, Bijlsma JWJ. Gastro-intestinale tolerantie van bisfosfonaten. Nederlands Tijdschrift voor Reumatologie 2004;4:47-51.

11

Reinders MK, van Roon EN, Brouwers JRBJ, Jansen TLTA. Effectiviteit van allopurinol en benzbromaron bij gecompliceerde jicht. Beleid zonder visie doet pijn. Pharmaceutisch Weekblad 2004;139(51):1710-3.

12

Vanhecke S, Penders E, Sarre S, de Walle HEK, Meijer WM, de Jong-van den Berg LTW. Foliumzuur rond de conceptie: De situatie in België. Farmaceutisch Tijdschrift voor België 2004;1:3-7.

13

Vroom F, de Jong PH, van den Berg PB, Tobi H, de Jong-van den Berg LTW. Gebruik van oral anticonceptiva in de jaren 1994-2002: wel anders, niet minder. Nederlands Tijdschrift Geneeskunde 2004;149(1):23-8.

Professional publications
1

Bouvy ML, Egberts ACG, de Jong-van den Berg LTW. Gevolgen van de publiciteit rondom de Million Women Study. Farmaco-epidemiologie van hormoonpaniek. Pharmaceutisch Weekblad 2004;139(14):473-4.

2

Brouwers JRBJ. Substitutiebeleid apothekers: kan het of kan het niet. Casuïstiek uit de gastro-enterologie. Pharmaceutisch Weekblad 2004;139(21):706.

3

Brouwers JRBJ, Harting JW, van Dullemen HM. Handvatten voor de selectie van protonpompremmers. Kiezen, loten of wegen. Pharmaceutisch Weekblad 2004;139(42):1382-6.

4

Brouwers JRBJ, van Luin M. Off-label-gebruik en verwisselbaarheid van NSAID's. Elk middel heeft zijn plek. Pharmaceutisch Weekblad 2004;139(26):910-1.

5

Brouwers JRBJ. Farmacotherapie van benigne prostaathyperplasie. Modern Medicine 2004;3:140-3.

6

Brouwers JRBJ. Protonpompremmers: preklinische data vertaalt naar de kliniek. Gastro Actueel 2004;8(10):-.

7

Frankhuisen R, Brouwers JRBJ, Otten MH. Antacida in de zwangerschap: welke zijn het veiligst? Modern Medicine 2004;(9):47-51.

8

Frankhuisen R, Brouwers JRBJ, Otten MH, Croonen HF. Aluminiumbevattende antacida niet veilig tijdens zwangerschap. WINAp-zelfzorgadvies klopt niet meer. Pharmaceutisch Weekblad 2004;139(41):1355-7.

9

Frijlink HW, Le Brun PPH, Brouwers JRBJ. Farmacokinetiek en toedieningsvormen. Waarom geavanceerd ook zinvol is. Pharmaceutisch Weekblad 2004;139(26):921-6.

10

de Jong-van den Berg LTW. Culturen en inzichten bepalen omvang hormoonsubstitutietherapie. Medicatisering staat tegenover gezond wantrouwen. Pharmaceutisch Weekblad 2004;139(14):488-91.

11

Loonen AJM. De zorg is geen handelsproduct. Medisch Contact 2004;59(40):1572-3.

12

Loonen AJM. Generiek lithiumcarbonaat geen alternatief voor Camcolit® en Priadel®. Lithium niet substitueren. Pharmaceutisch Weekblad 2004;139(42):1387.

13

Loonen AJM, Bakker JP. Verschraling behandelmogelijkheden in psychiatrie. Economische motieven belemmeren geneesmiddelonderzoek. Pharmaceutisch Weekblad 2004;139(39):1276-7.

14

Meijer WM. Kan foliumzuur ter preventie van foetale neurale buisdefecten ook minder vaak, maar in hogere dosering worden toegediend? Vademecum 2004;22(41):2-5.

15

Postma MJ, Jansen LMA, Brouwers JRBJ. Bruggen bouwen tussen vergoedingsbeleid en farmaco-economisch onderzoek. Procedures verschillen opvalllend. Pharmaceutisch Weekblad 2004;139(8):257-9.

16

Rijcken CAW, de Jong-van den Berg LTW. Zorg voor 1% van de Nederlandse bevolking. Schizofrenie daagt FPZ uit. Pharmaceutisch Weekblad 2004;139(4):132-5.

17

Schaafsma ES, Timmer JW, Tulp A. Laveren tussen Hyperglykemie en hypoglykemie na vergeten antidiabeticum (gemiste doseringen nr.6). Pharmaceutisch Weekblad 2004;139(11):368-70.

18

Schaafsma ES. Proefproject 'Ramadan en Medicijnen' in Den Haag. Zorg tijdens de Ramadan. Pharmaceutisch Weekblad 2004;139(41):1364-5.

19

van Strien A, Lind M, Versteeg E, de Gier JJ. Onderzoek gebruik protocollen. Samenwerking kan lonen. Pharmaceutisch Weekblad 2004;139(23):791-2.

20

Stuurman-Bieze A, de Jong-van den Berg LTW, Tromp ThFJ. Interventies op basis van pulmonaire medicatieprofielen. Een effectieve FPZ-interventiestrategie. Pharmaceutisch Weekblad 2004;139(52/53):1732-3.

21

Taxis K. Reducing intravenous drug errors. Hospital Pharmacy Europe 2004;14:40-2.

Whole book
1

Hovens JE, Loonen AJM, Timmerman L. Handboek neurobiologische psychiatrie. Utrecht: Tijdstroom, 2004

2

Jager J, Limburg W, Kretzschmar M, Postma MJ, Wiessing L. EMCDDA Monographs. Hepatitis C and injecting drug use: impact, costs and policy options. 7 ed. Luxembourg: Office for official publications of the european communities, 2004

3

Loonen AJM. Het beweeglijke brein. Badhoevedorp: Mension™ medical refresher, 2004

Book chapter
1

Kölling P, Loonen AJM. Man-vrouwverschillen in de psychiatrie. In: Hovens JE, Loonen AJM, Timmerman L, eds. Handboek Neurobiologische psychiatrie.Utrecht: De Tijdstroom Uitgeverij, 2004:129-33.

2

Loonen AJM. Neuropsychofarmacologie. In: Hovens JE, Loonen AJM, Timmerman L, eds. Handboek Neurobiologische psychiatrie.Utrecht: De Tijdstroom Uitgeverij, 2004:109-28.

3

Postma MJ, Wiessing LG, Jager JC. Updated healthcare cost estimate for drug-related hepatitis C infections in the European Union. In: Johannes Jager, Wien Limburg, Mirjam Kretzschmar, Maarten Postma, Lucas Wiessing, eds. EMCDDA Monographs. Hepatitis C and injecting drug use: impact, costs and policy options.Luxembourg: Office for official publications of the european communities, 2004:203-16.

4

Taxis K. Entries on clinical pharmacy. In: Ammon HPT, ed. Hunnius. Pharmazeutisches Wörterbuch. 9 ed. Berlin: Walter de Gruyter GmbH & Co. KG, 2004.

5

de Wit A, Bos JM. Cost-effectiveness of needle and syringe programmes: a review of the literature. In: Johannes Jager, Wien Limburg, Mirjam Kretzschmar, Maarten Postma, Lucas Wiessing, eds. EMCDDA Monographs. Hepatitis C and injecting drug use: impact, costs and policy options.Luxembourg: Office for official publications of the european communities, 2004:329-43.

Laatst gewijzigd:19 april 2016 09:34